TOLREMO therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
TOLREMO therapeutics General Information
Description
Operator of a biotechnology company intended to discover and develop small molecule therapies to prevent drug resistance and non-genetic cancer by dismantling the earliest defense to targeted therapies. The company develops add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs like adaptive drug resistance programs and molecules that eradicate cancer cells that cause drug resistance, enabling physicians to improve the response rates and get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Contact Information
Website
www.tolremo.comCorporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
Corporate Office
- Hochbergerstrasse 60C
- 4057 Basel
- Switzerland
TOLREMO therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 6. Later Stage VC (Series A) | 20-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series B) | 01-Jan-2021 | Cancelled | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 10-Jun-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 19-Sep-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Mar-2017 | Completed | Startup |
TOLREMO therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary | ||||||||
| Ordinary | 133,525 | $0.103523 | $3.11 | $3.11 | 1x | $3.11 | 2.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
TOLREMO therapeutics Comparisons
Industry
Financing
Details
TOLREMO therapeutics Competitors (26)
One of TOLREMO therapeutics’s 26 competitors is iOnctura, a Venture Capital-Backed company based in Genève, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| iOnctura | Venture Capital-Backed | Genève, Switzerland | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Cellestia | Venture Capital-Backed | Basel, Switzerland | ||||
| RootPath | Venture Capital-Backed | Framingham, MA |
TOLREMO therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TOLREMO therapeutics Patents
TOLREMO therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022253869-A1 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | Pending | 07-Apr-2021 | ||
| CA-3212085-A1 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | Active | 07-Apr-2021 | ||
| EP-4320109-A1 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | Pending | 07-Apr-2021 | ||
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | Active | 07-Apr-2021 | ||
| US-20240327394-A1 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | Pending | 07-Apr-2021 | C07D413/14 |
TOLREMO therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TOLREMO therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pierre Fabre | Holding Company | Minority | ||
| Altos Venture | Venture Capital | Minority | ||
| BioMedPartners | Venture Capital | Minority | ||
| Redalpine | Venture Capital | Minority | ||
| Wille Finance | Family Office | Minority |
TOLREMO therapeutics FAQs
-
When was TOLREMO therapeutics founded?
TOLREMO therapeutics was founded in 2017.
-
Where is TOLREMO therapeutics headquartered?
TOLREMO therapeutics is headquartered in Basel, Switzerland.
-
What is the size of TOLREMO therapeutics?
TOLREMO therapeutics has 14 total employees.
-
What industry is TOLREMO therapeutics in?
TOLREMO therapeutics’s primary industry is Drug Discovery.
-
Is TOLREMO therapeutics a private or public company?
TOLREMO therapeutics is a Private company.
-
What is TOLREMO therapeutics’s current revenue?
The current revenue for TOLREMO therapeutics is .
-
How much funding has TOLREMO therapeutics raised over time?
TOLREMO therapeutics has raised $55.7M.
-
Who are TOLREMO therapeutics’s investors?
Pierre Fabre, Altos Venture, BioMedPartners, Redalpine, and Wille Finance are 5 of 9 investors who have invested in TOLREMO therapeutics.
-
Who are TOLREMO therapeutics’s competitors?
iOnctura, Voyager Therapeutics, Anaveon, Cellestia, and RootPath are some of the 26 competitors of TOLREMO therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
